FDA approves new antibiotic from Durata Therapeutics for common skin infections
A new study suggests Canadians are interested in using electronic communications to help manage their health care.
The Associated Press
Published Friday, May 23, 2014 6:13PM EDT
WASHINGTON -- The Food and Drug Administration on Friday approved a new antibiotic from Durata Therapeutics Inc. to treat adults with common skin infections often acquired in U.S. hospitals.
Regulators approved the intravenous drug Dalvance to treat bacterial skin infections caused by common bacteria like Staphylococcus aureus, including antibiotic-resistant strains of those germs.
Antibiotics like penicillin and streptomycin first became widely available in the 1940s, and today dozens are still used to kill or suppress the bacteria behind illnesses ranging from strep throat to the plague. The drugs are considered one of the greatest advances in the history of medicine, and have saved countless lives.
But as decades passed, some antibiotics stopped working against germs they previously eliminated. Experts say overuse and misuse of the drugs by physicians have made them less effective.
The FDA gave Dalvance an expedited review, under a 2012 law designed to encourage research and development of new antibiotics. Under the measure, Chicago-based Durata will receive an additional five years of exclusive marketing rights on the drug.
The FDA said it approved Dalvance based on two trials of nearly 1,300 patients with skin and skin structure infections. The studies showed that Dalvance, known generically as dalbavancin, was as effective as vancomycin, another antibiotic.
The Centers for Disease Control and Prevention estimated last year that the staph infection MRSA, or methicillin-resistant Staphylococcus aureus, kills about 11,000 people.
Durata's stock ended Friday up 88 cents, or 5.5 per cent, at $16.89.